{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:16:12Z","timestamp":1788009372772,"version":"build-2784847793"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Health and Medical Research Council of Australia"},{"name":"Starship Children's Hospital Foundation"},{"name":"Medical Research Futures Fund of Australia"},{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health and Care Research in the United Kingdom"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council of the UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Lay Summary<\/jats:title>\n                  <jats:p>The Staphylococcus aureus Network Adaptive Platform trial is a whole-of-life infectious disease trial. Recently, results for the methicillin-susceptible Staphylococcus aureus domain in adults showed cefazolin is non-inferior to (flu)cloxacillin for S. aureus bacteremia. The trial continues in children. Here the investigators outline why.<\/jats:p>","DOI":"10.1093\/jpids\/piag073","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:42:08Z","timestamp":1786448528000},"source":"Crossref","is-referenced-by-count":0,"title":["The Courage to Continue: the\n                    <i>Staphylococcus aureus<\/i>\n                    Network Adaptive Platform Trial for Pediatrics and Youth"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-1155","authenticated-orcid":false,"given":"Asha C","family":"Bowen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital , Nedlands, WA ,","place":["Australia"]},{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia , Nedlands, WA ,","place":["Australia"]},{"name":"Medical School, The University of Western Australia , Nedlands, WA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5898-1126","authenticated-orcid":false,"given":"Anita J","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital , Nedlands, WA ,","place":["Australia"]},{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia , Nedlands, WA ,","place":["Australia"]},{"name":"Medical School, The University of Western Australia , Nedlands, WA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2026082908320206200_ref1","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciac476","article-title":"The Staphylococcus aureus network adaptive platform trial protocol: new tools for an old foe","volume":"75","author":"Tong","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026082908320206200_ref2","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamapediatrics.2024.2697","article-title":"Whole-of-life inclusion in Bayesian adaptive platform clinical trials","volume":"178","author":"Campbell","year":"2024","journal-title":"JAMA Pediatr"},{"key":"2026082908320206200_ref3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/cid\/ciae289","article-title":"Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomized controlled trial","volume":"79","author":"Anpalagan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026082908320206200_ref4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/cid\/ciad666","article-title":"Early oral antibiotic switch in Staphylococcus aureus bacteraemia: the Staphylococcus aureus Network Adaptive Platform (SNAP) trial early oral switch protocol","volume":"79","author":"de Kretser","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026082908320206200_ref5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s13063-023-07718-x","article-title":"A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial","volume":"24","author":"Mahar","year":"2023","journal-title":"Trials"},{"key":"2026082908320206200_ref6","doi-asserted-by":"publisher","first-page":"e20200134","DOI":"10.1542\/peds.2020-0134","article-title":"Clinical management of Staphylococcus aureus bacteremia in neonates, children, and adolescents","volume":"146","author":"McMullan","year":"2020","journal-title":"Pediatrics"},{"key":"2026082908320206200_ref7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an Antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2026082908320206200_ref8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapediatrics.2016.1477","article-title":"Epidemiology and mortality of Staphylococcus aureus bacteremia in Australian and New Zealand children","volume":"170","author":"McMullan","year":"2016","journal-title":"JAMA Pediatr"},{"key":"2026082908320206200_ref9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/cid\/ciab510","article-title":"Pediatric Staphylococcus aureus bacteremia: clinical spectrum and predictors of poor outcome","volume":"74","author":"Campbell","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026082908320206200_ref10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2026082908320206200_ref11","article-title":"Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial","volume":"408","author":"The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group","journal-title":"Lancet"},{"key":"2026082908320206200_ref12","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1056\/NEJMoa2506905","article-title":"Cefazolin for methicillin-susceptible Staphylococcus aureus bacteremia","volume":"394","author":"The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group","year":"2026","journal-title":"N Engl J Med"},{"key":"2026082908320206200_ref13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/cid\/ciad363","article-title":"Global differences in the management of Staphylococcus aureus bacteremia: no international standard of care","volume":"77","author":"Westgeest","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026082908320206200_ref14","doi-asserted-by":"publisher","first-page":"e12414","DOI":"10.1002\/ajum.12414","article-title":"Ultrasound evaluation of peripheral intravenous catheter thrombus formation associated with intravenous flucloxacillin administration: a prospective observational pilot study","volume":"28","author":"Bulmer","year":"2025","journal-title":"Australas J Ultrasound Med"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piag073\/70634204\/piag073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/8\/piag073\/70634204\/piag073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/8\/piag073\/70634204\/piag073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:32:08Z","timestamp":1788006728000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piag073\/8761062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piag073","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"piag073"}}